Laboratorio de Dermatologia e Imunodeficiencias (LIM-56), Departamento de Dermatologia, Faculdade de Medicina FMUSP, Institute de Medicina Tropical da Universidade de Sáo Paulo, Sáo Paulo, Brazil.
Front Public Health. 2022 Aug 15;10:963834. doi: 10.3389/fpubh.2022.963834. eCollection 2022.
The literature presents several reports of the impact of glycemic control and diabetes in the inflammatory and coagulatory response during coronavirus disease 2019 (COVID-19). Nevertheless, the long-term impact of the COVID-19 in diabetic patients is still to be explored. Therefore, we recruited 128 patients and performed a longitudinal analysis on COVID-19-associated biomarkers of patients with COVID-19, tree and 6 months after COVID-19 recovery and put into perspective the possible long-term complication generated after COVID-19. In our investigation, we failed to verify any long-term modification on inflammatory biomarkers, but detected an increase in the glycemia and glycated hemoglobin in patients without any pre-existing history or diagnosis of diabetes (non-diabetic patients). Although diabetic and non-diabetic patients presented elevated levels of glycated hemoglobin, the c-peptide test indicated a normal beta cell function in all patients.
文献报道了血糖控制和糖尿病对 2019 冠状病毒病（COVID-19）期间炎症和凝血反应的影响。然而，COVID-19 对糖尿病患者的长期影响仍有待探索。因此，我们招募了 128 名患者，对 COVID-19 患者的 COVID-19 相关生物标志物进行了纵向分析，在 COVID-19 康复后 3 个月和 6 个月，并从可能产生的 COVID-19 后长期并发症的角度进行了分析。在我们的研究中，我们未能证实炎症生物标志物有任何长期变化，但在没有任何既往糖尿病史或诊断的患者中发现血糖和糖化血红蛋白升高（非糖尿病患者）。尽管糖尿病和非糖尿病患者的糖化血红蛋白水平升高，但 C 肽试验表明所有患者的β细胞功能正常。
